- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Canakinumab – November 2017
Canakinumab: Powder for injection 150 mg with solvent, Solution for injection 150 mg in 1 mL; Ilari
Last updated
2 March 2018